REDWOOD CITY, CALIF, Jan. 4, 2013 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced that Chuck Bramlage, the Company’s president and CEO will be providing a corporate and clinical update at the 31st annual J.P. Morgan Healthcare Conference in San Francisco, CA. Mr. Bramlage’s presentation will include discussion of the Company’s inhaled, fixed-dose combination bronchodilator product candidate, PT003, and its monotherapy components, PT001 and PT005. Pearl’s presentation will take place on Wednesday, January 9, 2013 at 4:00pm Pacific Time.
